ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Two years after paying $1 billion to acquire Sprout Pharmaceuticals, maker of the female sexual dysfunction treatment Addyi (flibanserin), Valeant Pharmaceuticals is divesting the pill to former Sprout shareholders for next to nothing. After 18 months, Valeant will get a 6% royalty on sales of the drug, which has had limited sales since winning FDA approval in August 2015. Valeant will also loan $25 million to the Sprout shareholders to support initial operating expenses. The shareholders had sued Valeant, claiming it was not sufficiently marketing Addyi.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X